Eosinophilic granulomatosis with polyangiitis relapse after covid-19 vaccination: A case report
Costanzo G.
;Ledda A. G.;Ghisu A.;Vacca M.;Firinu D.;Del Giacco S.
2022-01-01
Abstract
Background: We here describe the case of a 71-year-old Caucasian woman previously diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA) that had been treated with Mepolizumab, an anti-IL5 monoclonal antibody, since 2019 with a good clinical response. Methods: She had a mild COVID-19 in December 2020 and she tested negative for SARS-CoV-2 infection in only late January 2021. In April 2021 she received the first dose of mRNA BNT162b2 vaccine. Ten days later she developed myalgia, dyspnea and numbness of the limbs due to a relapse of EGPA that occurred during Mepolizumab treatment.File | Size | Format | |
---|---|---|---|
vaccines-10-00013-v2 Eosinophilic Granulomatosis with Polyangiitis Relapse after COVID-19 Vaccination.pdf open access
Type: versione editoriale
Size 286.88 kB
Format Adobe PDF
|
286.88 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.